GPHD
This trial compares the efficacy and safety of tirzepatide once weekly at either 5 mg, 10 mg, 15 mg dose to 3 times a day Lispro in patients with type 2 diabetes on glargine.

Type of Study:
Parallel treatment study with 4 arms no masking.

Study Length:
26 Weeks

Target Age/Sex:
over 18 years, Male and Female

Benefits:
Participants will receive at no cost: study product, study materials and study-specific procedures

Staus: Enrolling

Description:

This trial compares the efficacy and safety of tirzepatide once weekly at either 5 mg, 10 mg, 15 mg dose to 3 times a day Lispro in patients with type 2 diabetes on glargine.

Enroll Now

Enroll Now

Address
Address
City
State/Province
Zip/Postal
If you don't have a primary care physician, just type "Do not have a primary care physician"